Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions that occurred from March 27-31. Deal Watch is supported by deal intelligence from Strategic Transactions.
A clinical development collaboration signed between Merck & Co. Inc. and Incyte Corp. in 2014 to test Merck's PD-1 inhibitor Keytruda (pembrolizumab) with Incyte's experimental selective IDO1 enzyme...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?